Krill Oil as Supplementation to Healthy Young Adults.

Not Applicable

Completed

• Conditions: Healthy
• Interventions: Dietary Supplement: Krill oil low dose; Dietary Supplement: Krill oil high dose

• Registration Number: NCT02053415
• Lead Sponsor: University of Bergen

Brief Summary

The purpose of this study is to examine whether 4 weeks daily intake of krill oil can change the omega-3 index (content of the long chained fatty acids EPA and DHA in relation to the total fatty acids) in the membrane in red blood cells. We investigate this at two different doses. Furthermore, the purpose of the study is also to examine the effect of the krill oil intake on plasma lipids (triacylglycerol, phospholipids and cholesterol), plasma fatty acid composition, as well as product tolerance in healthy, young individuals.

Detailed Description

Not available

Study Timeline

• Study Start: 2014-01
• Study First Submitted: 2014-01-31
• Study First Submitted QC: 2014-01-31
• Study First Posted: 2014-02-03
• Status Verified: 2014-03
• Primary Completion: 2014-03
• Study Completion: 2014-03
• Last Update Submitted: 2014-03-13
• Last Update Posted: 2014-03-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 35

Inclusion Criteria

• Healthy young adults

Exclusion Criteria

• Disease/illness
• Not able to swallow supplements in capsule form
• Not willing to take blood samples

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Krill oil low dose	Krill oil low dose	3 capsules krill oil per day, for 28 days
Krill oil high dose	Krill oil high dose	9 capsules krill oil per day, for 28 days

Primary Outcome Measures

Name	Time	Method
Fatty acid composition in red blood cells (the membrane)	Day 0 (baseline), and day 28 (end)	Change in fatty acid composition and omega-3 index (sum of % EPA and DHA)

Secondary Outcome Measures

Name	Time	Method
Fasting plasma lipid status	Day o (baseline), and day 28 (end)	* Change in triacylglycerol levels.; * Change in phospholipid levels.; * Change in cholesterol levels (total, ester, free, HDL, LDL).
Fatty acid composition in plasma.	Day 0 (baseline), and day 28 (end)	Change in fatty acid composition and omega-3 index (sum of % EPA and DHA).
Fasting glucose and glucose tolerance.	Day 0 (baseline), and day 28 (end)	Change in fasting glucose and glucose tolerance.
Tolerance of and compliance with intervention	Day 28 (end)	Questionnaire-based

Trial Locations

Locations (1)

Department of Clinical Science, University of Bergen; 🇳🇴 Bergen, Norway